ERBB2 and congestive heart failure: Pertuzumab in combination with trastuzumab and chemotherapy for HER2-positive cancer, nearly doubles the risk of CHF (risk ratio: 1.97) however, it does not significantly increase the risk of asymptomatic or minimally symptomatic left ventricular systolic dysfunction [80].